Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment
The gradual rise and fall of semaglutide levels creates less dramatic swings than youd see with shorter-acting medications
Tirzepatide is a dual agonist that targets GLP-1 and glucose-dependent insulinotropic polypeptide receptors
It is also one of the reasons that peptide formulations are typically buffered at slightly acidic pH, where deamidation is slower
These products carry risks and are not appropriate for everyone
Consult your healthcare provider Its not generally recommended to combine Wegovy and phentermine due to limited studies on their effects when taken together
